Literature DB >> 28802815

Shortening the duration of therapy for chronic hepatitis C infection.

Benjamin Emmanuel1, Eleanor M Wilson2, Thomas R O'Brien3, Shyam Kottilil1, George Lau4.   

Abstract

Combination direct-acting antiviral therapy of 8-24 weeks is highly effective for the treatment of chronic hepatitis C infection. However, shortening the treatment duration to less than 8 weeks could potentially reduce overall treatment costs and improve adherence. Here we explore the arguments for and against the development of short-duration regimens and existing data on treatment for 6 weeks or less among patients with chronic hepatitis C virus genotype 1 infection. Additionally, we identify potential predictors of response to short-course combination therapies with direct-acting antiviral drugs that might be explored in future clinical trials.
Copyright © 2017 Elsevier Ltd. All rights reserved.

Entities:  

Mesh：

Substances：

Year:  2017        PMID： 28802815      PMCID： PMC5737004          DOI： 10.1016/S2468-1253(17)30053-5

Source DB:  PubMed          Journal:  Lancet Gastroenterol Hepatol


  33 in total

1.  Efficacy of the Combination of Sofosbuvir, Velpatasvir, and the NS3/4A Protease Inhibitor GS-9857 in Treatment-Naïve or Previously Treated Patients With Hepatitis C Virus Genotype 1 or 3 Infections.

Authors:  Edward J Gane; Christian Schwabe; Robert H Hyland; Yin Yang; Evguenia Svarovskaia; Luisa M Stamm; Diana M Brainard; John G McHutchison; Catherine A Stedman
Journal:  Gastroenterology       Date:  2016-05-27       Impact factor: 22.682

2.  EASL Recommendations on Treatment of Hepatitis C 2016.

Authors: 
Journal:  J Hepatol       Date:  2016-09-22       Impact factor: 25.083

Review 3.  Treatment of hepatitis C: a systematic review.

Authors:  Anita Kohli; Ashton Shaffer; Amy Sherman; Shyam Kottilil
Journal:  JAMA       Date:  2014-08-13       Impact factor: 56.272

Review 4.  Modelling hepatitis C therapy--predicting effects of treatment.

Authors:  Alan S Perelson; Jeremie Guedj
Journal:  Nat Rev Gastroenterol Hepatol       Date:  2015-06-30       Impact factor: 46.802

Review 5.  Eight weeks of ledipasvir/sofosbuvir is effective for selected patients with genotype 1 hepatitis C virus infection.

Authors:  Kris V Kowdley; Vinay Sundaram; Christie Y Jeon; Kamran Qureshi; Nyan L Latt; Amandeep Sahota; Stephen Lott; Michael P Curry; Naoky Tsai; Nathorn Chaiyakunapruk; Yoori Lee; Jorg Petersen; Peter Buggisch
Journal:  Hepatology       Date:  2017-02-25       Impact factor: 17.425

6.  Cost-effectiveness and budget impact of hepatitis C virus treatment with sofosbuvir and ledipasvir in the United States.

Authors:  Jagpreet Chhatwal; Fasiha Kanwal; Mark S Roberts; Michael A Dunn
Journal:  Ann Intern Med       Date:  2015-03-17       Impact factor: 25.391

7.  Four-Week Direct-Acting Antiviral Regimens in Noncirrhotic Patients With Hepatitis C Virus Genotype 1 Infection: An Open-Label, Nonrandomized Trial.

Authors:  Anita Kohli; Sarah Kattakuzhy; Sreetha Sidharthan; Amy Nelson; Mary McLaughlin; Cassie Seamon; Eleanor Wilson; Eric G Meissner; Zayani Sims; Rachel Silk; Chloe Gross; Elizabeth Akoth; Lydia Tang; Angie Price; Tim A Jolley; Benjamin Emmanuel; Michael Proschan; Gebeyehu Teferi; Jose Chavez; Stephen Abbott; Anuoluwapo Osinusi; Hongmei Mo; Michael A Polis; Henry Masur; Shyam Kottilil
Journal:  Ann Intern Med       Date:  2015-11-24       Impact factor: 25.391

8.  Moderate Sustained Virologic Response Rates With 6-Week Combination Directly Acting Anti-Hepatitis C Virus Therapy in Patients With Advanced Liver Disease.

Authors:  Sarah Kattakuzhy; Eleanor Wilson; Sreetha Sidharthan; Zayani Sims; Mary McLaughlin; Angie Price; Rachel Silk; Chloe Gross; Elizabeth Akoth; Maryellen McManus; Benjamin Emmanuel; Shikha Shrivastava; Lydia Tang; Amy Nelson; Gebeyehu Teferi; Jose Chavez; Brian Lam; Hongmei Mo; Anuoluwapo Osinusi; Michael A Polis; Henry Masur; Anita Kohli; Shyamasundaran Kottilil
Journal:  Clin Infect Dis       Date:  2015-10-26       Impact factor: 9.079

Review 9.  APASL consensus statements and recommendation on treatment of hepatitis C.

Authors:  Masao Omata; Tatsuo Kanda; Lai Wei; Ming-Lung Yu; Wang-Long Chuang; Alaaeldin Ibrahim; Cosmas Rinaldi Adithya Lesmana; Jose Sollano; Manoj Kumar; Ankur Jindal; Barjesh Chander Sharma; Saeed S Hamid; A Kadir Dokmeci; Geofferey W McCaughan; Jafri Wasim; Darrell H G Crawford; Jia-Horng Kao; Osamu Yokosuka; George K K Lau; Shiv Kumar Sarin
Journal:  Hepatol Int       Date:  2016-04-29       Impact factor: 6.047

10.  High adherence to all-oral directly acting antiviral HCV therapy among an inner-city patient population in a phase 2a study.

Authors:  Tess Petersen; Kerry Townsend; Lori A Gordon; Sreetha Sidharthan; Rachel Silk; Amy Nelson; Chloe Gross; Monica Calderón; Michael Proschan; Anu Osinusi; Michael A Polis; Henry Masur; Shyam Kottilil; Anita Kohli
Journal:  Hepatol Int       Date:  2015-11-26       Impact factor: 6.047
View more
  10 in total

1.  Shortening Treatment for Hepatitis C Virus Infection.

Authors:  Shyam Kottilil
Journal:  Gastroenterol Hepatol (N Y)       Date:  2018-03

Review 2.  Glecaprevir/pibrentasvir expands reach while reducing cost and duration of hepatitis C virus therapy.

Authors:  Ameer Abutaleb; Shyam Kottilil; Eleanor Wilson
Journal:  Hepatol Int       Date:  2018-05-29       Impact factor: 6.047

3.  Impact of Direct Acting Antivirals on Survival in Patients with Chronic Hepatitis C and Hepatocellular Carcinoma.

Authors:  William M Kamp; Cortlandt M Sellers; Stacey Stein; Joseph K Lim; Hyun S Kim
Journal:  Sci Rep       Date:  2019-11-19       Impact factor: 4.379

4.  Effect of Direct-Acting Antiviral Agents on Gastroesophageal Varices in Patients with Hepatitis C Virus-Related Cirrhosis.

Authors:  Hiroshi Hisanaga; Hidetoshi Takedatsu; Keigo Emori; Hiroto Inoue; Yasuhumi Kunitake; Tomoyuki Nakane; Shuhei Fukunaga; Tatsuya Ide; Keiichi Mitsuyama; Takuji Torimura
Journal:  Medicina (Kaunas)       Date:  2022-08-10       Impact factor: 2.948

5.  JNJ-4178 (adafosbuvir, odalasvir, and simeprevir) in Japanese patients with chronic hepatitis C virus genotype 1 or 2 infection with or without compensated cirrhosis: the Phase IIa OMEGA-3 study.

Authors:  Tetsuo Takehara; Kazuaki Chayama; Masayuki Kurosaki; Hiroshi Yatsuhashi; Yasuhito Tanaka; Naoki Hiramatsu; Naoya Sakamoto; Yasuhiro Asahina; Akito Nozaki; Toshikazu Nakano; Yosuke Hagiwara; Hiroko Shimizu; Hiroki Yoshida; Yuhan Huang; Michael Biermer; Leen Vijgen; Norio Hayashi
Journal:  J Gastroenterol       Date:  2020-02-17       Impact factor: 7.527

6.  A systematic review and meta-analysis of community and primary-care-based hepatitis C testing and treatment services that employ direct acting antiviral drug treatments.

Authors:  Andrew Radley; Emma Robinson; Esther J Aspinall; Kathryn Angus; Lex Tan; John F Dillon
Journal:  BMC Health Serv Res       Date:  2019-10-28       Impact factor: 2.655

7.  Impact of Sustained Virological Response for Gastroesophageal Varices in Hepatitis-C-Virus-Related Liver Cirrhosis.

Authors:  Yukihisa Yuri; Hiroki Nishikawa; Hirayuki Enomoto; Kazunori Yoh; Yoshinori Iwata; Yoshiyuki Sakai; Kyohei Kishino; Naoto Ikeda; Tomoyuki Takashima; Nobuhiro Aizawa; Ryo Takata; Kunihiro Hasegawa; Noriko Ishii; Takashi Nishimura; Hiroko Iijima; Shuhei Nishiguchi
Journal:  J Clin Med       Date:  2019-12-30       Impact factor: 4.241

8.  Cost-Effectiveness Analysis of Pan-Genotypic Sofosbuvir-Based Regimens for Treatment of Chronic Hepatitis C Genotype 1 Infection in China.

Authors:  Hui Jun Zhou; Jing Cao; Hui Shi; Nasheen Naidoo; Sherehe Semba; Pei Wang; Yi Fan Fan; Shui Cheng Zhu
Journal:  Front Public Health       Date:  2021-12-09

9.  Treatment optimisation for hepatitis C in the era of combination direct-acting antiviral therapy: a systematic review and meta-analysis.

Authors:  Christopher R Jones; Barnaby F Flower; Ella Barber; Bryony Simmons; Graham S Cooke
Journal:  Wellcome Open Res       Date:  2019-09-06

10.  High Cure Rates for Hepatitis C Virus Genotype 6 in Advanced Liver Fibrosis With 12 Weeks Sofosbuvir and Daclatasvir: The Vietnam SEARCH Study.

Authors:  Barnaby Flower; Leanne McCabe; Chau Le Ngoc; Hung Le Manh; Phuong Le Thanh; Thuan Dang Trong; Thu Vo Thi; Hang Vu Thi Kim; Thanh Nguyen Tat; Dao Phan Thi Hong; An Nguyen Thi Chau; Tan Dinh Thi; Nga Tran Thi Tuyet; Joel Tarning; Cherry Kingsley; Evelyne Kestelyn; Sarah L Pett; Guy Thwaites; Vinh Chau Nguyen Van; David Smith; Eleanor Barnes; M Azim Ansari; Hugo Turner; Motiur Rahman; Ann Sarah Walker; Jeremy Day; Graham S Cooke
Journal:  Open Forum Infect Dis       Date:  2021-06-09       Impact factor: 3.835
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.